Omnicell, Inc. (OMCL)
Healthcare · NMS
Price as at 30 Sept 2026, 22:42 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Omnicell, Inc. trades at $34.05, which is 19% above the $27.63 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 43 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 92.7 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
OMCL earnings and analyst estimates
Recommendation mix, 8 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
OMCL passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
10 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$72.01M · 0.0% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$37.89M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$33.00M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$24.76M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$11.94M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in OMCL
Trades in OMCL disclosed by members of Congress and executive-branch officials, latest first:
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 29 Jul 2024 · disclosed 22 Sept 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
OMCL peers
The largest companies in the same industry (Health Information Services), then in the same sector.
- PME.AX Pro Medicus Limited
- HNGE Hinge Health, Inc.
- WAY Waystar Holding Corp.
- PRVA Privia Health Group, Inc.
- HTFL Heartflow, Inc.
- CERT Certara, Inc.
- TALK Talkspace, Inc.
- HSTM HealthStream, Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Omnicell, Inc. (OMCL) undervalued?
Against our fair value estimate of $27.63, OMCL at $34.05 is 19% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own OMCL?
10 of the institutions we track reported a position in OMCL in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is OMCL's P/E ratio?
OMCL trades at 92.7 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Where does SteadyShares get its OMCL data?
Fundamentals for OMCL come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 22:42 UTC and is delayed. Our data quality score for this company is 92/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for OMCL, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.